Rituxan maintenance for TTP – pro
Rituximab, an anti-CD20 chimeric monoclonal antibody, has been used successfully to treat patients with relapsed or refractory thrombotic thrombocytopenic purpura (TTP), and some patients relapse when the therapy is started, and require maintenance. Only case reports and retrospective reviews are available in the literature. Froissart recommends deciding about the duration of maintenance based on ADAMTS13.
Vinai C. Bhagirath etal,Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion Volume 52, Issue 12 December 2012, Pages 2517–2523
J-P. Westwood et al,Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse JTH Volume 11, Issue 3 March 2013 Pages 481–490.
Antoine Froissart, Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. November 2015Volume 26, Issue 9, Eur J Int Med Pages 659–665